AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06355258
Drug: placebo + low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 IU LMWH once a day + Oral placebo tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily
Trial: NCT06355258
Drug: troxerutin + low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 IU LMWH once a day + Oral troxerutin tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily
Trial: NCT05279235
Drug: JT001 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 1: 600mg, Q12H X 1 day; Day 2\~5: 300mg, Q12H X 4 days
Trial: NCT06215989
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo one tablet once daily will be given on the basis of standard treatment of ACS recommended by guidelines
Trial: NCT04977336
Drug: HB/APAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules for oral administration.
Trial: NCT05898984
Drug: Reference product 2 (R2): BDP HFA (QVAR REDIHALER®, BDP 80 μg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pressurised, breath-actuated, metered dose aerosol with a dose counter): 8 inhalations (TDD of BDP: 640 µg ex-actuator, 800 µg ex valve).
Trial: NCT06058442
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-15 capsules of placebo per day - over 6 months
Trial: NCT06239194
Drug: MDX2001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDX2001 intravenous infusion
Trial: NCT05193916
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no active drug contained
Trial: NCT04715542
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered with subcutaneous injections 3 times a week at 1 ampoule at 1 mL during the chemotherapy and shall be continued during 6 weeks after the end of chemotherapy . The first injection will be administered on the day of the first dose of chemotherapy, before the injection of the first dose of chemotherapy.
Trial: NCT06176599
Drug: Shenxiao Yuning decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astragalus 30g, Radix Pseudostellariae 15g, Rehmannia glutinosa 15g, Rhodiola rosea 12g，Cimicifuga 15g，Cuttlebone 15g，Poria 15g，Cicada degeneration 9g，Rheum palmatum 6g.
Trial: NCT06176599
Drug: Symptomatic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (i) Diabetes education: all study participants were given dietary guidance for diabetic nephropathy, low-fat, high-quality, low-protein diet, and restricted sodium intake; maintain emotional stability, quit smoking and alcohol, and exercise appropriately; (ii) control of blood glucose: all study participants routinely received hypoglycaemic treatment, hypoglycaemic measures are not limited (including oral hypoglycaemic drugs or insulin injection); (iii) Control of lipids: study participants with substandard lipids routinely receive lipid-lowering treatment; (iv) Control of blood pressure: those with blood pressure \&gt;140/90 mmHg should be treated with antihypertensive drugs to control blood pressure, and antihypertensive measures are not limited (CCB class, ACEI or ARB class, α, β-blockers, diuretics, etc.); ⑤ Other symptomatic treatment.
Trial: NCT05615363
Drug: OPC 131461 10mg group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPC-131461 5 mg tablet x 2，once-daily oral administration for 14 days
Trial: NCT05615363
Drug: OPC 131461 5mg group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPC-131461 5 mg tablet and placebo tablet，once-daily oral administration for 14 days
Trial: NCT05615363
Drug: OPC 131461 2mg group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPC-131461 1 mg tablet x 2，once-daily oral administration for 14 days
Trial: NCT05615363
Drug: OPC 131461 1mg group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPC-131461 1 mg tablet and placebo tablet，once-daily oral administration for 14 days
Trial: NCT05615363
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet，once-daily oral administration for 14 days
Trial: NCT06667934
Drug: Zuoqing powder was dissolved in 100ml normal saline, retained enema, once a night
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zuoqing powder was dissolved in 100ml normal saline, retained enema, once a night
Trial: NCT05110794
Drug: LY3502970
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered Orally.
Trial: NCT06682130
Drug: Group A：Patients with PR or ctDNA positivity after salvage treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Immunotargeted therapy~   * Ottuzumab introvenous infusion, 1000mg day1;~  * Glofitamab introvenous infusion Group A: 2.5mg day8~2. Autologous stem cell transplantation SEAM regimen~   * Simustine 250mg/m2 orally, day1~  * Etoposide 200mg/m2 intravenous infusion, day2-5~  * Cytarabine 400mg/m2 intravenous infusion, day2-5~  * Metformin 140mg/m2 intravenous infusion, day6; Patients in Group A who intend to receive Glofitamab+ASCT will receive Glofitamab 2.5mg on day8 and start ASCT pretreatment on day15.
Trial: NCT06682130
Drug: Group C: Patients with SD/PD after posterior treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Immunotargeted therapy~   * Ottuzumab introvenous infusion, 1000mg day1;~  * Glofitamab introvenous infusion Group C: cycle1 2.5mg day8, 10mg day15 cycle2 30mg day21~2. Autologous stem cell transplantation SEAM regimen~   * Simustine 250mg/m2 orally, day1~  * Etoposide 200mg/m2 intravenous infusion, day2-5~  * Cytarabine 400mg/m2 intravenous infusion, day2-5~  * Metformin 140mg/m2 intravenous infusion, day6;~After two treatment cycles with Glofitamab, patients in group C had a PET-CT to assess efficacy. Those with partial remission proceeded to ASCT consolidation, those with complete remission chose between ASCT or Glofitamab maintenance, and those with stable disease or progressive disease exited the trial.
Trial: NCT05204927
Drug: 177Lu-PSMA-I&T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioligand therapy
Trial: NCT06665087
Drug: Ultrafractionated RT and CGA Guided systemic treatment.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: in cohort 1, all patients will receive Ultrafractionated RT (1Fx every 3 or 4weeks) and Sintilimab (q3w). Furthermore, CGA will assess all patients and classify them into Frail, Vulnerabe, or Fit. Frail patients will receive Best Supportive Care (BSC); Vulnerabe patients will receive Fluorouracil/Raltitrexed, with/without targeted therapy, and BSC; Fit patients will receive Fluorouracil/Raltitrexed, Oxaliplatin/Irinotecan, with/without targeted therapy, and BSC.
Trial: NCT06665087
Drug: Targeted Therapy (anti-VEGF)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-VEGF antibody
Trial: NCT06665087
Drug: Targeted Therapy (anti-EGFR)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-EGFR antibody
Trial: NCT06058520
Drug: Placebo drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo consists of a mixture of trehalose and crystalline methylcellulose (Avicel) in 6:1 (w/w) ratio that is packaged in size 0 swedish orange capsules, which are then double encapsulated in size 00 natural colored capsules to make them visibly indistinguishable from encapsulated active product.
Trial: NCT04837508
Drug: MRG002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administrated intravenously
Trial: NCT03843463
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill manufactured to mimic escitalopram 10 mg tablet
Trial: NCT05751512
Drug: Methotrexate Injection
RxNorm normalized name: methotrexate Injection
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously
Trial: NCT05497479
Drug: 0.003% AR-15512 to be administered in both eyes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two rounds of Schirmer tests, performed without anesthetic (per randomization), before and after instillation of 0.003% AR-15512
Trial: NCT05497479
Drug: Vehicle to be administered in both eyes
RxNorm normalized name: Born To Be Mild
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two rounds of Schirmer tests, performed without anesthetic, before and after instillation of Vehicle
Trial: NCT05497479
Drug: 0.003% AR-15512 to be administered in both eyes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two rounds of Schirmer tests, performed with anesthetic (per randomization), before and after instillation of 0.003% AR-15512
Trial: NCT05497479
Drug: Vehicle to be administered in both eyes
RxNorm normalized name: Born To Be Mild
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two rounds of Schirmer tests, performed with anesthetic (per randomization), before and after instillation of Vehicle
Trial: NCT06682611
Drug: HB1801
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In accordance with the protocol
Trial: NCT05720130
Drug: [²¹²Pb]Pb-ADVC001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ph1b Escalation~Drug: \[²¹²Pb\]Pb-ADVC001administered intravenously per dose escalation scheme~Dose Level 1~- 60 MBq, 4 cycles every 6 weeks~Dose Level 2a~- 120 MBq, 4 to 6 cycles every 4 weeks~Dose Level 2b~- Optional cohort of 120 MBq, 4 to 6 cycles every 2 weeks~Dose Level 3a~- 160 MBq, 4 to 6 cycles every 4 weeks~Dose Level 3b~- Optional cohort of 160 MBq, 4 to 6 cycles every 2 weeks~Dose Level 4a~- 200 MBq, 4 to 6 cycles every 4 weeks~Dose Level 4b~- Optional cohort of 200 MBq, 4 to 6 cycles every 2 weeks~Ph2a Expansion~Drug: \[²¹²Pb\]Pb-ADVC001 at recommended phase 2 dose and schedule
Trial: NCT06576960
Drug: Nano silver fluoride varnish and tri calcium phosphate varnish
RxNorm normalized name: silver fluoride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride varnishes
Trial: NCT05360160
Drug: ASTX727
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by PO
Trial: NCT05083936
Drug: [18F]FET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imaging evaluation using LAT1/4F2hc substrate overexpressed in brain tumor
Trial: NCT05429970
Drug: Etodolac
RxNorm normalized name: Etodolac
DrugBank: Etodolac (DB00749)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etodolac 400 mg PO BID (for 21 consecutive days)
Trial: NCT06457425
Drug: Flonoltinib 50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flonoltinib 50mg
Trial: NCT06457425
Drug: Flonoltinib 100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flonoltinib 100mg
Trial: NCT06200311
Drug: Pharmacological rhythm management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1st line: rate control, 2nd line: pharmacological rhythm management. 3rd line: AF ablation
Trial: NCT04544293
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT05580666
Drug: Azithromycin Oral Tablet
RxNorm normalized name: azithromycin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial therapy
Trial: NCT05426486
Drug: ARX788
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HER2 antibody-drug conjugate
Trial: NCT06233916
Drug: [14C] D-1553
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[14C\] D-1553 (approximately 400 mg/80 μCi)
Trial: NCT06683833
Drug: Egyptian MTA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Complete caries removal from the cavity.~* The liquid of Egyptian MTA (Toothmate) will be mixed with powder according to the manufacturers' instructions.~* The capping materials will be placed with the passive application on the deepest part of the cavity. Only light pressure will be applied on the MTA mixture using a wet cotton pellet to ensure adaptation of the material onto the dentin.~* A light-cured glass ionomer cement base will be applied in the cavity .~* Selective enamel etching will be applied on enamel only.~* The one-bottle universal adhesive system bond will be applied on enamel and dentine.~* A Nano hybrid composite resin material will then be incrementally inserted into the cavities.
Trial: NCT06683833
Drug: Biodentine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Complete caries removal from the cavity.~* Gently tapping a capsule of Biodentine (Septodont) on a hard surface to loosen the powder, then opening the capsule, Detaching a single-dose container of liquid and gently tapping on the sealed cap to force all the liquid down the container, Twisting cap to open, Then Pouring 5 drops from the single-dose container into the capsule, Then Closing the capsule and Placing it on a mixing device for 30 seconds, Then Collecting Biodentine with the instrument supplied in the box.~* The capping materials will be placed with the passive application on the deepest part of the cavity.~* A light-cured glass ionomer cement base will be applied in the cavity .~* Selective enamel etching will be applied on enamel only.~* The one-bottle universal adhesive system bond will be applied on enamel and dentine.~* A Nano hybrid composite resin material will then be incrementally inserted into the cavities.
Trial: NCT06683833
Drug: Calcium Hydroxide (Ca(OH)2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Complete caries removal from the cavity.~* According to the manufacturers' instructions, Dispensing equal volumes of base and catalyst pastes on the parchment paper pad provided. Using a Dycal (Dentsply) Liner applicator, stirring immediately to mix thoroughly until a uniform color is achieved, complete mixing occurs within 10 seconds, using the ball-pointed Dycal Liner applicator or similar instrument, the mix will be placed directly on the cavity.~* The capping materials will be placed with the passive application on the deepest part of the cavity.~* A light-cured glass ionomer cement base will be applied in the cavity .~* Selective enamel etching will be applied on enamel only.~* The one-bottle universal adhesive system bond will be applied on enamel and dentine.~* A Nano hybrid composite resin material will then be incrementally inserted into the cavities.
Trial: NCT05184062
Drug: 600mg placebo IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomized to receive co-administration of 600mg placebo by a single IV infusion.
Trial: NCT04791319
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered subcutaneously.
Trial: NCT06697431
Drug: Intravenous Immunoglobulins, Human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: see previous section
Trial: NCT06419686
Drug: GIP
RxNorm normalized name: GIP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous GIP administration during experimental days.
Trial: NCT06419686
Drug: Alanine
RxNorm normalized name: Alanine
DrugBank: Alanine (DB00160)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alanine administration during experimental days.
Trial: NCT06419686
Drug: GIP + alanine
RxNorm normalized name: Alanine
DrugBank: Alanine (DB00160)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous administration of GIP and alanine during experimental days.
Trial: NCT02137525
Drug: Fentanyl 100 µg
RxNorm normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl sublingual spray - single unit delivering 100 µg fentanyl
Trial: NCT02137525
Drug: Fentanyl 200 µg
RxNorm normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl sublingual spray - single unit delivering 200 µg fentanyl
Trial: NCT02137525
Drug: Fentanyl 400 µg
RxNorm normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl sublingual spray - single unit delivering 400 µg fentanyl
Trial: NCT02137525
Drug: Placebo Sublingual Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching sublingual spray - single unit delivering 0 µg fentanyl
Trial: NCT06699472
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vincristine (V), intravenous injection, 1.5 mg/m2 (maximum not exceeding 2mg), D1, odd cycle administration Doxorubicin (D), intravenous infusion, 75mg/m2, D1, odd cycle administration When the cumulative dose of doxorubicin is ≥ 375mg/m2, replace it with actinomycin D 1.25mg/m2 Cyclophosphamide (C), intravenous infusion, 1200mg/m2, D1, odd cycle administration Ifosfamide (I), intravenous infusion, 1800mg/m2, D1-5, even cycle administration Etoposide (E), intravenous infusion, 100mg/m2, D1-5, even cycle administration
Trial: NCT06627309
Drug: Dara IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treament follow the clinical routine practice, as daratumumab 16mg/kg iv qw OR dara SC 1800mg initially. The treatment schedule involve weekly administrations during cycles 1 to 2, following by biweekly administrations during cycles 3 to 6. Subsequently, monthly administrations are given as monotherapy.
Trial: NCT06627309
Drug: Cyclophosphamide (CTX)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Some patients may receive cyclophosphamide orally or intravenously at a dosage of 300 mg/m2 weekly.
Trial: NCT06627309
Drug: Dara SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treament follow the clinical routine practice, as daratumumab 16mg/kg iv qw OR dara SC 1800mg initially. The treatment schedule involve weekly administrations during cycles 1 to 2, following by biweekly administrations during cycles 3 to 6. Subsequently, monthly administrations are given as monotherapy.
Trial: NCT06604689
Drug: third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib)
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGFR-mutated NSCLC patients with brain metastases who met the inclusion and exclusion criteria, would receive first-line third-generation EGFR-TKI treatment (monotherapy or combined with upfront cranial radiotherapy)
Trial: NCT05113888
Drug: Qizhi weitong granules(High）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: take orally before meals, 1 bag each time, 3 times a day.
Trial: NCT05113888
Drug: Qizhi weitong granules(Low）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: take orally before meals, 1 bag each time, 3 times a day.
Trial: NCT05113888
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: take orally before meals, 1 bag each time, 3 times a day.
Trial: NCT06380699
Drug: QHRD106 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-tissue kallikrein-1
Trial: NCT06380699
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00416858
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05018403
Drug: Intravenous AON-D21
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AON-D21 is a Pegylated L-configured aptamer that binds and thereby neutralizes the complement component C5a from activating both C5a receptors.
Trial: NCT05018403
Drug: Intravenous placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic glucose solution identical in appearance to AON-D21.
Trial: NCT06186479
Drug: Aconite pain oil
RxNorm normalized name: aconite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants apply 6 ml oil topically 2 times per day (morning and evening) for 15 to 27 weeks on chemotherapy-free days as long as they receive chemotherapy.
Trial: NCT06186479
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants apply 6 ml oil topically 2 times per day (morning and evening) for 15 to 27 weeks on chemotherapy-free days as long as they receive chemotherapy.
Trial: NCT05121103
Drug: EZM0414
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release film-coated tablets: Six dose levels starting at 100 mg, and then 200 mg, 300 mg, 400 mg, 600 mg, and 900 mg as well as an optional step-down dose level of 75 mg (if needed)
Trial: NCT03865615
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05673239
Drug: Levocarnitine Injection
RxNorm normalized name: levocarnitine Injection
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients in the test group were injected with 1-2g (10-20mg/kg) levocarnitine on each dialysis day
Trial: NCT05139615
Drug: APD418
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single dose of APD418 as an intravenous (IV) infusion.
Trial: NCT04875702
Drug: Naproxen 250 MG
RxNorm normalized name: naproxen 250 MG
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen 250 mg p.o. twice daily
Trial: NCT04875702
Drug: Naproxen 500 Mg
RxNorm normalized name: naproxen 500 MG
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dose escalation to 500 mg twice daily for patients experiencing breakthrough flares.
Trial: NCT04515706
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of Iguratimod
Trial: NCT05519384
Drug: JK500 cell injection，cyclophosphamide，Fludarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After enrollment, patients received JK500 cell injection infusion after reinduction therapy. Pretreatment regimen before cell infusion: intravenous infusion of cyclophosphamide 60mg/kg day -7, intravenous infusion of fludarabine 25mg/㎡/day day -6 to -2 days. In order to activate and expand circulating NK cells, on the day of each infusion of JK500 cells, the patients were first subcutaneously injected with 100WU/ m2 of interleukin (IL)-2 0.5h-1h in advance, for a total of 6 doses.
Trial: NCT05318248
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo pill